Previous 10 | Next 10 |
BETHLEHEM, Pa., July 31, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its OMNIgene®·ORAL (OM-505) saliva collecti...
LENEXA, Kan. , July 31, 2020 /PRNewswire/ -- Today, Clinical Reference Laboratory (CRL), one of the largest privately held clinical testing laboratories in the U.S., announced that it received FDA Emergency Use Authorization (EUA) and is scaling up capacity for CRL Rapid Response ...
2020 Second Quarter Earnings Conference Call Wednesday, August 5, 2020, 5:00 p.m. ET BETHLEHEM, Pa., July 22, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2020 second quarter financial results and certa...
The following slide deck was published by OraSure Technologies, Inc. in conjunction with this Read more ...
ST. PAUL, Minn., June 25, 2020 (GLOBE NEWSWIRE) -- Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ:OSUR), and Alimentiv Inc. (formerly Robarts Clinical Trials) today announced they have signed a collaboration agreement for a research study on patients with Acute Severe U...
OraSure Technologies' (NASDAQ: OSUR ) unit, DNA Genotek is introducing OMNImet GUT (ME-200), first in-home, self-collection of fecal samples device for metabolomics. More news on: OraSure Technologies, Inc., Healthcare stocks news, Read more ...
OTTAWA, June 17, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services is introducing the first and only commercially available device for in-home, self-c...
MORRISVILLE, N.C. , June 17, 2020 /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomics, and DNA Genotek, a subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), have collaborated to bring OMNImet™·GUT, the first device for in-home collection and ambient-temper...
OraSure Technologies (NASDAQ: OSUR ) has been awarded a $629,217 contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop an Enzyme-Linked Immunosorbent Assay (ELISA) for the detection of human anti-SARS-CoV-2 antibodies in oral fluid specimens. More ne...
BETHLEHEM, Pa., June 10, 2020 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices and microbiome laboratory and analytical services, today announced it has been awarded a $629,217 contract from the Biomedical...
News, Short Squeeze, Breakout and More Instantly...
OraSure Technologies Inc. Company Name:
OSUR Stock Symbol:
NASDAQ Market:
OraSure Technologies Inc. Website:
BETHLEHEM, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering second quarter 2024 financial results and certain business developments for 5 p.m. ET on August 6, 2024. A webcast of the conference call w...
2024-07-02 09:00:08 ET Vijay Kumar from Evercore ISI issued a price target of $4.50 for OSUR on 2024-07-02 08:07:00. The adjusted price target was set to $4.50. At the time of the announcement, OSUR was trading at $4.27. OSUR currently trades -49.59% versus its 52 week h...
BETHLEHEM, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced its support of HIV testing initiatives taking place across the nation in recognition of National HIV Tes...